

July 2, 2010

Astellas Nominates President of OSI Pharmaceuticals, Inc.

Japan, July 2, 2010 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that it has nominated Naoki Okamura as President of OSI Pharmaceuticals, Inc. ("OSI"), which is a wholly-owned subsidiary of Astellas US Holding, Inc., a holding company owned by Astellas Pharma Inc.

Particulars

Name of President: Naoki Okamura
Last Department: Licensing & Alliances, Astellas Pharma Inc.
Effective Date: July 2, 2010

Astellas completed the acquisition of OSI through a short form merger on June 8, 2010. OSI is a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing medical needs in oncology, diabetes and obesity. OSI commercializes Tarceva® (erlotinib), a leading cancer medication, and has several prospective new oncology medications in its R&D pipeline. The acquisition of OSI is expected to augment Astellas' strong existing franchises in urology and transplantation, expanding the product portfolio and pipeline of the combined company.

#####

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com/en